JP2021191802A5 - - Google Patents

Download PDF

Info

Publication number
JP2021191802A5
JP2021191802A5 JP2021155526A JP2021155526A JP2021191802A5 JP 2021191802 A5 JP2021191802 A5 JP 2021191802A5 JP 2021155526 A JP2021155526 A JP 2021155526A JP 2021155526 A JP2021155526 A JP 2021155526A JP 2021191802 A5 JP2021191802 A5 JP 2021191802A5
Authority
JP
Japan
Prior art keywords
product
formulation
weight
chloride
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021155526A
Other languages
English (en)
Japanese (ja)
Other versions
JP7705326B2 (ja
JP2021191802A (ja
Filing date
Publication date
Priority claimed from US16/715,998 external-priority patent/US10814001B1/en
Application filed filed Critical
Publication of JP2021191802A publication Critical patent/JP2021191802A/ja
Publication of JP2021191802A5 publication Critical patent/JP2021191802A5/ja
Priority to JP2025014721A priority Critical patent/JP2025065198A/ja
Application granted granted Critical
Publication of JP7705326B2 publication Critical patent/JP7705326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021155526A 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法 Active JP7705326B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014721A JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US62/844,069 2019-05-06
US62/843,819 2019-05-06
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/715,998 2019-12-16
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/716,014 2019-12-16
JP2020045468A JP7141420B2 (ja) 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020045468A Division JP7141420B2 (ja) 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014721A Division JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Publications (3)

Publication Number Publication Date
JP2021191802A JP2021191802A (ja) 2021-12-16
JP2021191802A5 true JP2021191802A5 (cg-RX-API-DMAC7.html) 2023-09-26
JP7705326B2 JP7705326B2 (ja) 2025-07-09

Family

ID=72750169

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020045468A Active JP7141420B2 (ja) 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2021155526A Active JP7705326B2 (ja) 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2025014721A Pending JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020045468A Active JP7141420B2 (ja) 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014721A Pending JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Country Status (17)

Country Link
US (11) US10799481B1 (cg-RX-API-DMAC7.html)
EP (1) EP3965737A1 (cg-RX-API-DMAC7.html)
JP (3) JP7141420B2 (cg-RX-API-DMAC7.html)
KR (3) KR102410503B1 (cg-RX-API-DMAC7.html)
CN (2) CN117045596A (cg-RX-API-DMAC7.html)
AU (1) AU2020268329A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022404A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139443A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002918A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015265A2 (cg-RX-API-DMAC7.html)
IL (1) IL287831A (cg-RX-API-DMAC7.html)
MA (1) MA55895A (cg-RX-API-DMAC7.html)
MX (1) MX2021013516A (cg-RX-API-DMAC7.html)
PE (1) PE20220384A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112272TA (cg-RX-API-DMAC7.html)
WO (1) WO2020227260A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202108950B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8466174B2 (en) 2006-03-17 2013-06-18 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
MX2008013783A (es) 2006-04-26 2009-02-05 Aciex Inc Composiciones para el tratamiento y prevención de la hinchazón de los párpados.
WO2008070185A2 (en) 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
US20090281156A1 (en) * 2007-12-21 2009-11-12 Schering-Plough Healthcare Products, Inc, Enhancing photostabilization of oxymetazoline
PL2262506T3 (pl) * 2008-03-11 2014-09-30 Alcon Res Ltd Wysoce sflokulowane zawiesiny acetonidu triamcynolonu o niskiej lepkości do wystrzykiwania do ciała szklistego
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
CN103249429A (zh) * 2010-11-08 2013-08-14 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
WO2012075319A2 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2013177594A2 (en) 2012-05-25 2013-11-28 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN111465309B (zh) 2013-09-18 2021-11-30 迈康尼股份公司 用于组件的改进的存储和处理的方法、系统和设备
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders

Similar Documents

Publication Publication Date Title
JP2021191802A5 (cg-RX-API-DMAC7.html)
JP2018021007A5 (cg-RX-API-DMAC7.html)
JP2020007356A5 (cg-RX-API-DMAC7.html)
JP6886502B2 (ja) アトロピン含有水性組成物
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
JP2016534142A5 (cg-RX-API-DMAC7.html)
JP2005508981A5 (cg-RX-API-DMAC7.html)
JP2008540532A5 (cg-RX-API-DMAC7.html)
JP2010529999A5 (cg-RX-API-DMAC7.html)
JP2013501717A5 (cg-RX-API-DMAC7.html)
JP2006516032A5 (cg-RX-API-DMAC7.html)
JP2019536761A5 (cg-RX-API-DMAC7.html)
JP2011105739A5 (cg-RX-API-DMAC7.html)
SI3193835T1 (en) Liquid inhalation preparation containing rpl554
CA2717605A1 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
JP2016512210A5 (cg-RX-API-DMAC7.html)
JP2014515383A5 (cg-RX-API-DMAC7.html)
JP2011026335A5 (cg-RX-API-DMAC7.html)
JP2005530822A5 (cg-RX-API-DMAC7.html)
JP2008523090A5 (cg-RX-API-DMAC7.html)
JP2025114800A5 (cg-RX-API-DMAC7.html)
JP2007501817A5 (cg-RX-API-DMAC7.html)
CA2535533A1 (en) Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
JP2019151627A5 (cg-RX-API-DMAC7.html)
RU2014115289A (ru) Композиция пазопаниба